[go: up one dir, main page]

TN2011000187A1 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
TN2011000187A1
TN2011000187A1 TN2011000187A TN2011000187A TN2011000187A1 TN 2011000187 A1 TN2011000187 A1 TN 2011000187A1 TN 2011000187 A TN2011000187 A TN 2011000187A TN 2011000187 A TN2011000187 A TN 2011000187A TN 2011000187 A1 TN2011000187 A1 TN 2011000187A1
Authority
TN
Tunisia
Prior art keywords
organic compounds
alky
polymorphs
hydrates
diol
Prior art date
Application number
TN2011000187A
Other languages
English (en)
Inventor
Michael Mutz
Guido Jordine
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42062355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000187(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2011000187A1 publication Critical patent/TN2011000187A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08Acetic acid
    • C07C53/10Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/122Propionic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/08Malonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/10Succinic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08Lactic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255Tartaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04Monocyclic monocarboxylic acids
    • C07C63/06Benzoic acid
    • C07C63/08Salts thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
TN2011000187A 2008-11-11 2011-04-19 Organic compounds TN2011000187A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08168862 2008-11-11
PCT/EP2009/064889 WO2010055027A2 (fr) 2008-11-11 2009-11-10 Composés organiques

Publications (1)

Publication Number Publication Date
TN2011000187A1 true TN2011000187A1 (en) 2012-12-17

Family

ID=42062355

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000187A TN2011000187A1 (en) 2008-11-11 2011-04-19 Organic compounds

Country Status (20)

Country Link
US (2) US8680146B2 (fr)
EP (1) EP2358660A2 (fr)
JP (2) JP2012508215A (fr)
KR (1) KR20110086142A (fr)
CN (2) CN102256933A (fr)
AU (1) AU2009315735B2 (fr)
BR (1) BRPI0921533A2 (fr)
CA (1) CA2741974A1 (fr)
CL (1) CL2011001041A1 (fr)
CO (1) CO6382154A2 (fr)
EC (1) ECSP11011121A (fr)
IL (1) IL212073A0 (fr)
MA (1) MA32877B1 (fr)
MX (1) MX2011004924A (fr)
NZ (1) NZ591999A (fr)
PE (1) PE20120012A1 (fr)
RU (1) RU2543621C2 (fr)
TN (1) TN2011000187A1 (fr)
WO (1) WO2010055027A2 (fr)
ZA (1) ZA201102272B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101321742B (zh) 2005-05-26 2012-08-29 神经元系统公司 用于治疗视网膜疾病的组合物和方法
US8680146B2 (en) * 2008-11-11 2014-03-25 Novartis Ag Organic compounds
EP2896609B1 (fr) * 2009-07-24 2018-06-27 ratiopharm GmbH Citrate de fingolimod crystallin pour le traitement de la sclérose en plaques récurrente-rémittente
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
WO2012056458A2 (fr) 2010-10-28 2012-05-03 Mapi Pharma Ltd. Composés intermédiaires et procédé de préparation de fingolimod
WO2012071524A1 (fr) 2010-11-24 2012-05-31 Ratiopharm Gmbh Sels d'arylsulfonates de fingolimod et leurs procédés de préparation
EP2505589A1 (fr) 2011-04-01 2012-10-03 Johann Wolfgang Goethe-Universität Frankfurt am Main Nouveaux composés hétérocycliques de sphingolipides en tant que modulateurs de la signalisation de sphingolipides et leurs utilisations
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
CN111135171B (zh) 2013-01-23 2023-09-08 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
AU2014224237B2 (en) 2013-03-05 2017-07-20 Biocon Limited A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
CN105611917A (zh) 2013-10-11 2016-05-25 帝国制药美国公司 局部鞘氨醇-1-磷酸酯受体激动剂制剂及其使用方法
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CA2974375A1 (fr) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Forme galenique solide stable de fingolimod
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
JP7116490B2 (ja) 2016-05-09 2022-08-10 アルデイラ セラピューティクス, インコーポレイテッド 眼の炎症性障害および疾患の組合せ処置
RU2732572C2 (ru) 2016-05-31 2020-09-21 Тайхо Фармасьютикал Ко., Лтд. Сульфонамидное соединение или его соль
RU2627691C1 (ru) * 2016-07-06 2017-08-10 Олег Ростиславович Михайлов Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス, インコーポレイテッド 炎症性障害の処置
BR112020010148A2 (pt) 2017-11-29 2020-10-13 Taiho Pharmaceutical Co., Ltd. compostos de sulfonamida e uso dos mesmos
AU2019293260A1 (en) * 2018-06-29 2021-01-07 Forma Therapeutics, Inc. Salts of (S)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)(cyclopropyl)methanone and solid forms thereof
CN112714762A (zh) * 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
CA3156298A1 (fr) 2019-10-31 2021-05-06 Laetitia POUZOL Combinaison d'un antagoniste de cxcr7 avec un modulateur du recepteur s1p1
JP2023526016A (ja) 2020-05-13 2023-06-20 アルデイラ セラピューティクス, インコーポレイテッド 医薬製剤およびその使用
JP2024521882A (ja) * 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用
EP4212156A1 (fr) 2022-01-13 2023-07-19 Abivax Combinaison de 8-chloro-n-(4-(trifluorométhoxy)phényl)quinolin-2-amine et de ses dérivés avec un modulateur de récepteur de s1p

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406B1 (fr) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. Compose 2-amino-1,3-propanediol et immunosuppresseur
ECSP951461A (es) 1995-06-07 1998-04-07 SINTESIS DE 3- {4-(2- AMINOETOXI) BENZOIL]-2-ARIL-6- HIDROXIBENZO {b] TIOFENOS (CASO X- 9295B)
ECSP972265A (es) 1997-09-23 1998-11-30 Dihidrato de d-olanzapina
FR2785607B1 (fr) 1998-11-09 2001-02-09 Rhodia Chimie Sa Procede de preparation de tris(ether-amine)
PT1129066E (pt) * 1998-11-11 2005-05-31 Taito Co Producao de 2-amino-2-[2-(4-c2-20-alquil-fenil)etil]propano-1,3-diois
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
CN1524002A (zh) * 2001-06-08 2004-08-25 ��˹��ŵ�� 治疗或预防产胰岛素细胞的移植排斥反应
PT1505959E (pt) * 2002-05-16 2009-02-05 Novartis Ag Utilização de agentes de ligação do receptor edg em cancro
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
US20060275357A1 (en) 2003-04-08 2006-12-07 Tomoyuki Oomura Organic compounds
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
US20080221200A1 (en) * 2005-09-30 2008-09-11 Malcolm Allison Combination of Organic Compounds
EP2046315B1 (fr) * 2006-06-02 2013-04-10 The Ohio State University Research Foundation Agents thérapeutiques destinés au traitement du lymphome a cellules du manteau
US7985586B2 (en) * 2008-02-04 2011-07-26 Georgia Health Sciences University Oligodendrocyte precursor cell composition and methods of use
US8680146B2 (en) * 2008-11-11 2014-03-25 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US8680146B2 (en) 2014-03-25
IL212073A0 (en) 2011-06-30
US20110218248A1 (en) 2011-09-08
NZ591999A (en) 2013-06-28
EP2358660A2 (fr) 2011-08-24
PE20120012A1 (es) 2012-02-02
MX2011004924A (es) 2011-05-30
CL2011001041A1 (es) 2011-10-07
CO6382154A2 (es) 2012-02-15
WO2010055027A3 (fr) 2010-08-19
AU2009315735B2 (en) 2013-01-10
MA32877B1 (fr) 2011-12-01
WO2010055027A2 (fr) 2010-05-20
AU2009315735A1 (en) 2010-05-20
RU2011123365A (ru) 2012-12-20
RU2543621C2 (ru) 2015-03-10
ECSP11011121A (es) 2011-07-29
JP2012508215A (ja) 2012-04-05
CN105198760A (zh) 2015-12-30
ZA201102272B (en) 2011-12-28
CN102256933A (zh) 2011-11-23
CA2741974A1 (fr) 2010-05-20
JP2015178503A (ja) 2015-10-08
BRPI0921533A2 (pt) 2016-01-12
US20140235722A1 (en) 2014-08-21
KR20110086142A (ko) 2011-07-27

Similar Documents

Publication Publication Date Title
TN2011000187A1 (en) Organic compounds
MY153915A (en) Organic compounds
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
IN2012DN00624A (fr)
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
EP2297140A4 (fr) Nouveaux composés de 1,2,4-oxadiazole et leurs procédés d'utilisation
UA105390C2 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
AP2010005480A0 (en) Small molecule inhibitors for the treatment or prevention of denque virus infection.
MX2011007750A (es) Composiciones y metodos para inhibicion de la ruta jak.
JO2892B1 (en) CYP inhibitors 17
WO2010055028A3 (fr) Composés organiques
WO2007115821A3 (fr) Composés organiques
MX2013004570A (es) Mezclas fungicidas de penflufen.
MX2012004780A (es) Inhibidores de akt.
LT2252300T (lt) 2,4-pirimidindiaminų panaudojimas aterosklerozės gydymui
ZA200908612B (en) 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MY150600A (en) Use of opioid antagonists for treating urinary retention
EP2499120A4 (fr) Nouveaux composés de 1,3-oxazolidine et utilisation de ces derniers comme inhibiteurs de la rénine
WO2010074936A3 (fr) Enzastaurine dans le traitement du cancer
CL2007000773A1 (es) Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd.
GB201020397D0 (en) Compounds
MX2010001303A (es) Compuestos terapeuticos.